Toll Free: 1-888-928-9744

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H1 2016

Published: Apr 20, 2016 | Pages: 607 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H1 2016', provides an overview of the Chronic Obstructive Pulmonary Disease (COPD) pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Chronic Obstructive Pulmonary Disease (COPD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Obstructive Pulmonary Disease (COPD) and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Chronic Obstructive Pulmonary Disease (COPD)
- The report reviews pipeline therapeutics for Chronic Obstructive Pulmonary Disease (COPD) by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Chronic Obstructive Pulmonary Disease (COPD) therapeutics and enlists all their major and minor projects
- The report assesses Chronic Obstructive Pulmonary Disease (COPD) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Chronic Obstructive Pulmonary Disease (COPD)

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Chronic Obstructive Pulmonary Disease (COPD)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Chronic Obstructive Pulmonary Disease (COPD) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope 
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Content 2 Introduction 7 Chronic Obstructive Pulmonary Disease (COPD) Overview 8 Therapeutics Development 9 Chronic Obstructive Pulmonary Disease (COPD) - Therapeutics under Development by Companies 11 Chronic Obstructive Pulmonary Disease (COPD) - Therapeutics under Investigation by Universities/Institutes 21 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Products Glance 22 Chronic Obstructive Pulmonary Disease (COPD) - Products under Development by Companies 26 Chronic Obstructive Pulmonary Disease (COPD) - Products under Investigation by Universities/Institutes 40 Chronic Obstructive Pulmonary Disease (COPD) - Companies Involved in Therapeutics Development 41 Chronic Obstructive Pulmonary Disease (COPD) - Therapeutics Assessment 150 Drug Profiles 170 Chronic Obstructive Pulmonary Disease (COPD) - Recent Pipeline Updates 449 Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects 546 Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products 568 Chronic Obstructive Pulmonary Disease (COPD) - Product Development Milestones 574 Appendix 583
List of Tables
Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD), H1 2016 32 Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD) - Comparative Analysis, H1 2016 33 Number of Products under Development by Companies, H1 2016 35 Number of Products under Development by Companies, H1 2016 (Contd..1) 36 Number of Products under Development by Companies, H1 2016 (Contd..2) 37 Number of Products under Development by Companies, H1 2016 (Contd..3) 38 Number of Products under Development by Companies, H1 2016 (Contd..4) 39 Number of Products under Development by Companies, H1 2016 (Contd..5) 40 Number of Products under Development by Companies, H1 2016 (Contd..6) 41 Number of Products under Development by Companies, H1 2016 (Contd..7) 42 Number of Products under Development by Companies, H1 2016 (Contd..8) 43 Number of Products under Investigation by Universities/Institutes, H1 2016 44 Comparative Analysis by Late Stage Development, H1 2016 45 Comparative Analysis by Clinical Stage Development, H1 2016 46 Comparative Analysis by Early Stage Development, H1 2016 47 Comparative Analysis by Unknown Stage Development, H1 2016 48 Products under Development by Companies, H1 2016 49 Products under Development by Companies, H1 2016 (Contd..1) 50 Products under Development by Companies, H1 2016 (Contd..2) 51 Products under Development by Companies, H1 2016 (Contd..3) 52 Products under Development by Companies, H1 2016 (Contd..4) 53 Products under Development by Companies, H1 2016 (Contd..5) 54 Products under Development by Companies, H1 2016 (Contd..6) 55 Products under Development by Companies, H1 2016 (Contd..7) 56 Products under Development by Companies, H1 2016 (Contd..8) 57 Products under Development by Companies, H1 2016 (Contd..9) 58 Products under Development by Companies, H1 2016 (Contd..10) 59 Products under Development by Companies, H1 2016 (Contd..11) 60 Products under Development by Companies, H1 2016 (Contd..12) 61 Products under Development by Companies, H1 2016 (Contd..13) 62 Products under Investigation by Universities/Institutes, H1 2016 63 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by AB2 Bio Ltd., H1 2016 64 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Abeona Therapeutics, Inc. , H1 2016 65 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Ache Laboratorios Farmaceuticos S/A, H1 2016 66 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Achillion Pharmaceuticals, Inc., H1 2016 67 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Adamis Pharmaceuticals Corporation, H1 2016 68 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Advinus Therapeutics Ltd., H1 2016 69 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Alchemia Limited, H1 2016 70 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by AlgiPharma AS, H1 2016 71 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Allinky Biopharma, H1 2016 72 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Amakem NV, H1 2016 73 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Ampio Pharmaceuticals, Inc., H1 2016 74 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Angion Biomedica Corp., H1 2016 75 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Apellis Pharmaceuticals, Inc., H1 2016 76 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Aridis Pharmaceuticals LLC, H1 2016 77 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Ario Pharma Ltd, H1 2016 78 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Astellas Pharma Inc., H1 2016 79 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by AstraZeneca Plc, H1 2016 80 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Asubio Pharma Co., Ltd., H1 2016 82 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Axikin Pharmaceuticals, Inc., H1 2016 83 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Beech Tree Labs, Inc., H1 2016 84 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Bioneer Corporation, H1 2016 85 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Biotie Therapies Corp., H1 2016 86 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Boehringer Ingelheim GmbH, H1 2016 87 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by C4X Discovery Holdings PLC, H1 2016 88 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Carolus Therapeutics, Inc., H1 2016 89 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Cellular Biomedicine Group, Inc., H1 2016 90 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Chiesi Farmaceutici SpA, H1 2016 91 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Circassia Pharmaceuticals Plc, H1 2016 92 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by CSL Limited, H1 2016 93 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Cytokinetics, Inc., H1 2016 94 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Daiichi Sankyo Company, Limited, H1 2016 95 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Domainex Limited, H1 2016 96 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Dong Wha Pharma Co., Ltd., H1 2016 97 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Elsalys Biotech SAS, H1 2016 98 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by enGene, Inc, H1 2016 99 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Errant Gene Therapeutics, LLC, H1 2016 100 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 101 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Five Prime Therapeutics, Inc., H1 2016 102 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Foresee Pharmaceuticals, LLC, H1 2016 103 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Galapagos NV, H1 2016 104 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Gilead Sciences, Inc., H1 2016 105 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by GlaxoSmithKline Plc, H1 2016 106 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2016 107 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by iCeutica, Inc., H1 2016 108 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by InMed Pharmaceuticals Inc., H1 2016 109 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Innate Pharma S.A., H1 2016 110 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by INVENT Pharmaceuticals, Inc., H1 2016 111 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Invion Limited, H1 2016 112 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Jiangsu Hansoh Pharmaceutical Co., Ltd., H1 2016 113 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Johnson & Johnson, H1 2016 114 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by KaloBios Pharmaceuticals, Inc., H1 2016 115 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Kissei Pharmaceutical Co., Ltd., H1 2016 116 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2016 117 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Ligand Pharmaceuticals, Inc., H1 2016 118 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Medestea Research & Production S.p.A., H1 2016 119 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Merck & Co., Inc., H1 2016 120 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Mereo Biopharma Group Limited, H1 2016 121 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Microbion Corporation, H1 2016 122 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Nivalis Therapeutics, Inc., H1 2016 123 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Nostrum Pharmaceuticals, LLC, H1 2016 124 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Novabiotics Limited, H1 2016 125 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Novartis AG, H1 2016 126 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Odan Laboratories Ltd., H1 2016 127 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by OPKO Health, Inc., H1 2016 128 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Orion Oyj, H1 2016 129 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Otsuka Holdings Co., Ltd., H1 2016 130 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Panmira Pharmaceuticals, LLC., H1 2016 131 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Peptinnovate Limited, H1 2016 132 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Pfizer Inc., H1 2016 133 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by PharmaLundensis AB, H1 2016 134 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Pharmaxis Limited, H1 2016 135 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Polyphor Ltd., H1 2016 136 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Promedior, Inc., H1 2016 137 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by ProMetic Life Sciences Inc., H1 2016 138 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Proteostasis Therapeutics, Inc., H1 2016 139 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Pulmagen Therapeutics LLP, H1 2016 140 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Pulmatrix, Inc., H1 2016 141 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Quark Pharmaceuticals, Inc., H1 2016 142 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Re-Pharm Limited, H1 2016 143 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Recipharm AB, H1 2016 144 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Respira Therapeutics, Inc., H1 2016 145 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Respiratorius AB, H1 2016 146 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by rEVO Biologics, Inc., H1 2016 147 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Rhizen Pharmaceuticals S.A., H1 2016 148 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Seoul Pharma Co., Ltd., H1 2016 149 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by SkyePharma Plc, H1 2016 150 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Spring Bank Pharmaceuticals, Inc., H1 2016 151 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Stelic Institute & Co., Inc., H1 2016 152 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by sterna biologicals Gmbh & Co KG, H1 2016 153 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Sucampo Pharmaceuticals, Inc., H1 2016 154 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Sun Pharma Advanced Research Company Ltd., H1 2016 155 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Sunovion Pharmaceuticals Inc., H1 2016 156 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Synovo GmbH, H1 2016 157 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Syntrix Biosystems, Inc., H1 2016 158 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 159 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Teva Pharmaceutical Industries Ltd., H1 2016 160 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Therabron Therapeutics, Inc., H1 2016 161 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Theraclone Sciences, Inc., H1 2016 162 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Theravance Biopharma, Inc., H1 2016 163 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Torrent Pharmaceuticals Limited, H1 2016 164 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Unizyme Laboratories A/S, H1 2016 165 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Vectura Group Plc, H1 2016 166 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Verona Pharma Plc, H1 2016 167 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Vertex Pharmaceuticals Incorporated, H1 2016 168 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by vTv Therapeutics LLC, H1 2016 169 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Yuhan Corporation, H1 2016 170 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Yungjin Pharm. Co., Ltd., H1 2016 171 Chronic Obstructive Pulmonary Disease (COPD) - Pipeline by Zambon Company S.p.A., H1 2016 172 Assessment by Monotherapy Products, H1 2016 173 Assessment by Combination Products, H1 2016 174 Number of Products by Stage and Target, H1 2016 176 Number of Products by Stage and Mechanism of Action, H1 2016 183 Number of Products by Stage and Route of Administration, H1 2016 190 Number of Products by Stage and Molecule Type, H1 2016 192 Chronic Obstructive Pulmonary Disease (COPD) Therapeutics - Recent Pipeline Updates, H1 2016 472 Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects, H1 2016 569 Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..1), H1 2016 570 Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..2), H1 2016 571 Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..3), H1 2016 572 Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..4), H1 2016 573 Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..5), H1 2016 574 Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..6), H1 2016 575 Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..7), H1 2016 576 Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..8), H1 2016 577 Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..9), H1 2016 578 Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..10), H1 2016 579 Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..11), H1 2016 580 Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..12), H1 2016 581 Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..13), H1 2016 582 Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..14), H1 2016 583 Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..15), H1 2016 584 Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..16), H1 2016 585 Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..17), H1 2016 586 Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..18), H1 2016 587 Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..19), H1 2016 588 Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..20), H1 2016 589 Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects (Contd..21), H1 2016 590 Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products, H1 2016 591 Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products (Contd..1), H1 2016 592 Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products (Contd..2), H1 2016 593 Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products (Contd..3), H1 2016 594 Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products (Contd..4), H1 2016 595 Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products (Contd..5), H1 2016 596


List of Figures
Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD), H1 2016 32 Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD) - Comparative Analysis, H1 2016 33 Number of Products under Development by Companies, H1 2016 34 Number of Products under Investigation by Universities/Institutes, H1 2016 44 Comparative Analysis by Late Stage Development, H1 2016 45 Comparative Analysis by Clinical Stage Development, H1 2016 46 Comparative Analysis by Early Stage Products, H1 2016 47 Assessment by Monotherapy Products, H1 2016 173 Assessment by Combination Products, H1 2016 174 Number of Products by Top 10 Targets, H1 2016 175 Number of Products by Stage and Top 10 Targets, H1 2016 175 Number of Products by Top 10 Mechanism of Actions, H1 2016 182 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 182 Number of Products by Top 10 Routes of Administration, H1 2016 189 Number of Products by Stage and Top 10 Routes of Administration, H1 2016 189 Number of Products by Top 10 Molecule Types, H1 2016 191 Number of Products by Stage and Top 10 Molecule Types, H1 2016 191

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global air traffic control equipment market is projected to reach USD 4.2 billion by 2020, as per a new research report by Radiant Insights, Inc. Mounting price sensitivity among customers with introduction of low fare airlines is expected to drive t

Read More...

Global contact lenses market size is estimated to reach USD 12.5 billion by 2020, according to a new industry report by Radiant Insights, Inc. Growing number of ophthalmic disorder observed in global population especially children is likely to drive

Read More...

Global gas sensors market is expected to reach USD 2,512.4 million by 2020, as per a new research report by Radiant Insights, Inc. High adoption rate of wireless and smart gas sensor technology coupled with escalating demand from end-use industries s

Read More...

Global engineering service outsourcing market size is likely to be valued at USD 415.7 billion by 2020, as per a new research report by Radiant Insights, Inc. Rapid alignment of OEMs accompanied by increasing focus on efficient performance and reliab

Read More...

Global thermoplastic polyurethane (TPU) films market size is likely to be valued at USD 724.6 million by 2020; as per a new research report by Radiant Insights, Inc. Increase in lightweight plastics demand in order to achieve vehicle fuel efficiency

Read More...
Choose License Type
Single User - US $2000
Multi User - US $4000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify